INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients

Authors

Parminder Singh, Mayo Clinic
Jason A. Efstathiou, Massachusetts General Hospital
Catherine Tangen, Fred Hutchinson Cancer Research Center
Sameer G. Jhavar, Scott and White Hospital
Noah M. Hahn, Johns Hopkins School of Medicine
Brian Addis Costello, Mayo Clinic
Scott Edward Delacroix, LSUHSC New OrleansFollow
Abhishek Tripathi, University of Oklahoma Health Sciences Center
Sean Sachdev, Northwestern University
Jessie Gills, Louisiana State University
Ashesh B. Jani, Lithuania
Rick Bangs, Emory University
Melissa Plets, SWOG
Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada
Ian Murchie Thompson, Christus Santa Rosa Medical Center Hospital
Felix Y. Feng, Northwestern Memorial Hospital
Seth P. Lerner, University of California, San Francisco

Document Type

Article

Publication Date

3-2-2021

Publication Title

Journal of Clinical Oncology

Volume

39(6_suppl)

Comments

Abstract Number: 428 2021 Genitourinary Cancers Symposium

Recommended Citation

Singh, Parminder; Efstathiou, Jason A.; Tangen, Catherine; Jhavar, Sameer G.; Hahn, Noah M.; Costello, Brian Addis; Delacroix, Scott Edward; Tripathi, Abhishek; Sachdev, Sean; Gills, Jessie; Jani, Ashesh B.; Bangs, Rick; Plets, Melissa; Vogelzang, Nicholas J.; Thompson, Ian Murchie; Feng, Felix Y.; and Lerner, Seth P., "INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients" (2021). School of Medicine Faculty Publications. 1132.
https://digitalscholar.lsuhsc.edu/som_facpubs/1132